Connect with us

Hi, what are you looking for?

Jewish Business News

Business

FDA awards Israeli stem cell co Pluristem orphan drug status

PLX-PAD cells treatment for severe preeclampsia is among the most common medical complications of pregnancy

pluristem- MEDICAL HEALTH ISRAEL 768x432

 

Israeli placenta-based cell therapy developer Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) has been awarded orphan drug status by the US Food and Drug Administration (FDA) for its PLX-PAD cells treatment for severe preeclampsia.

Preeclampsia is among the most common medical complications of pregnancy and a leading cause of premature births, stillbirths and neonatal and maternal deaths. There is no cure except delivery. Due to high risks to the mother, women diagnosed with severe preeclampsia are usually delivered promptly, even if the baby will be born prematurely and may suffer permanent disabilities as a result. Severe preeclampsia occurs in approximately 1% of pregnancies in Western countries.

Benefits of Orphan Drug Designation for PLX-PAD cells include close guidance that may accelerate time to marketing approval, orphan drug grants, tax credits, and a 7-year market exclusivity upon marketing approval. It is estimated by different sources that preeclampsia costs the global health care system about $3 billion annually.

 

Click to comment

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement